Natalia Rost, MD, MPH, FAAN, FAHA, chief of the stroke division at Massachusetts General Hospital and chair of the American Academy of Neurology (AAN) Science Committee, previews the annual meeting and provides a glimpse into what the conference has to offer and its legacy of 75 years.
Natalia Rost, MD, MPH, FAAN, FAHA, chief of the stroke division at Massachusetts General Hospital and chair of the American Academy of Neurology (AAN) Science Committee, talks about the offerings of the 2023 annual meeting taking place April 22-27 in Boston, Massachusetts.
Transcript
What can attendees look forward to at the 75th American Academy of Neurology (AAN) Annual Meeting?
It’s a platinum jubilee for us as an organization. As you know, the Academy is the largest professional organization of neurologists and neuroscience and neurology professionals in the world with more than 40,000 members. We're really excited to bring this celebration of neurology into Boston, and again offer to our members an in-person as well as virtual format. There's going to be something for everybody.
There's more than 3000 original submissions, translated into over 26 presentations: 400 of them in a scientific platform format, and more than 2000 poster presentations. So whatever neurological subspecialty you're coming from, whether it's stroke, movement disorders, epilepsy, many more, you're going to be able to find a platform presentation that you'd be interested in. Or you're going to be able to browse the “poster neighborhoods” as we call them, to find some of the exciting science. In addition to that, we have 7 plenary sessions that are spread out over 6 days. We have more than a number of research hub presentations, which are less of a structured, and more of a bring-science-closer-to-the-members format. We have invited science sessions, we have neuroscience in the clinic sessions, so as you can see, there's a lot going to be going on. That's in addition to education, advocacy, practice, and all sorts of other fun sessions that we're going to be offering to the members, including our epic opening party that's going to take place in the Boston Museum of Science.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More